The role of rectal chloride secretion in childhood constipation by Bekkali, N.L.H. (Noor) et al.
The role of rectal chloride secretion in childhood
constipation
N. BEKKALI,* H. R. DE JONGE, R. M. J. G. J. VAN DEN WIJNGAARD, A. F. W. VAN DER STEEG,§ P. B. BIJLSMA,*
J. A. J. M. TAMINIAU,* J. F. DESJEUX– & M. A. BENNINGA*
*Department of Paediatric Gastroenterology and Nutrition, Emma Children’s Hospital, Amsterdam, The Netherlands
Department of Biochemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
§Department of paediatric Surgery, Emma Children’s Hospital, Amsterdam, The Netherlands
–Chaire de Biologie, Conservatoire national des arts et me´tiers, Paris, France
Abstract
Background Disturbance in fluid secretion, driven by
chloride secretion, might play a role in constipation.
However, disturbed chloride secretion in those patients
has yet to be evaluated. Therefore, the aim of this study
was to compare chloride secretion in rectal biopsies of
children with functional constipation (FC) to those
without constipation.Methods To measure changes in
short circuit current (Isc in lA cm
)2) reflecting chloride
secretion, intestinal biopsies from children with con-
stipation, to either exclude or diagnose Hirschsprung’s
disease, and from children without constipation (con-
trols) undergoing colonoscopy for screening of familial
adenomatous polyposis, juvenile polyps or inflamma-
torybowel disease (IBD),were compared and studied in
Ussing chambers. Following electrogenic sodium
absorption blockade by amiloride, chloride secretory
responses to calcium-linked (histamine, carbachol) and
cAMP-linked (IBMX/forskolin) secretagogues were
assessed. Key Results Ninety-six patients (46 FC) par-
ticipated; nine FC patients (n = 1 congenital syndrome
and n = 8 technical problems) and 13 controls (n = 6
IBD; n = 7 technical problems) were excluded. No sig-
nificant difference was found in mean (±SE) basal
chloride currents between children with FC and con-
trols (9.6 ± 1.1 vs 9.2 ± 0.8; P = 0.75, respectively).
Responses to calcium-linked chloride secretagogues
(histamine and carbachol) were significantly higher in
controls (33.0 ± 3.0 vs 24.5 ± 2.3; P = 0.03 and
33.6 ± 3.4 vs 26.4 ± 2.7; P = 0.05 following histamine
and carbachol, respectively). Conclusions &
Inferences Calcium-linked chloride secretion is dis-
turbed in children with FC. Whether this defect occurs
at the level of histamine receptors, components of
receptor-linked signal transduction pathways or baso-
lateral Ca2+-sensitive K+ channels enhancing the elec-
trical driving force for apical chloride secretion,
remains to be explored.
Keywords Children, chloride secretion, constipation,
Ussing chamber.
Abbreviations: CFTR, cystic fibrosis transmembrane con-
ductance regulator; FC, functional constipation.
INTRODUCTION
The intestinal epithelium has important ion transport
capacity with chloride as the predominant electrolyte
driving fluid secretion in the colon.1 The intestine and
the organs draining into it, secrete approximately 8 L of
fluid per day of which only 200 mL leaves the body
within the stool.2,3 It is evident that pathological
consequences will follow when chloride secretion
increased or reduced as occurs in secretory diarrhea
or cystic fibrosis, respectively.4,5
Two major proteins required for active chloride
secretion are the Na/K/2Cl co-transporter (NKCC1)
for chloride import and the cystic fibrosis transmem-
brane conductance regulator (CFTR) for chloride
export, both located mainly in the crypts.6 In cystic
fibrosis, many newborns present with meconiumileus,
where thickened, dehydrated intestinal secretions
cause intestinal obstruction shortly after birth.
Therefore, disturbance in fluid secretion might also
play a role in constipation.1
Address for Correspondence
Noor Bekkali, MD, PhD, Department of Paediatric Gastro-
enterology and Nutrition, Academic Medical Centre, Emma
Children’s Hospital, Office C2-312, Meibergdreef 9, 1105 AZ
Amsterdam, The Netherlands.
Tel: +31 20 5662906; fax: +31 20 6917033;
e-mail: n.bekkali@amc.nl
Received: 2 February 2011
Accepted for publication: 23 May 2011
Neurogastroenterol Motil (2011) 23, 1007–1012 doi: 10.1111/j.1365-2982.2011.01751.x
 2011 Blackwell Publishing Ltd 1007
Chloride secretion stimulators act as selective chlo-
ride channel activators in the apical membrane of the
gastrointestinal (GI) epithelium increasing intestinal
chloride secretion and thereby intraluminal fluid col-
lection in the gut, such as lubiprostone.7 Just recently,
our group showed that lubiprostone stimulates chloride
secretion by activation of the CFTR channel rather than
by the earlier described ClC-2 channel.7–9 Interestingly,
in adults with constipation, those stimulators were
found to be efficient in increasing defecation frequency
and in softening stools.10–12 However, a disturbance in
gut CFTR expression or activation in patients with
constipationremains tobeevaluated, e.g., bymonitoring
transepithelial chloride secretion in Ussing chambers.
Although Ussing chambers are widely used for the
characterization of GI ion transport in animal models,
studies in human tissue have been fairly limited due to
the scarce availability of adequately sized sam-
ples.7,13,14 In recent years, miniaturized container
inserts which enclose smaller biopsy specimens and
low volume Ussing chambers, have been developed to
facilitate studies in human tissue.15,16 In this study,
using such a miniaturized Ussing chamber system, we
evaluated changes in chloride currents (as a measure
for chloride secretion) ex vivo, in the rectal biopsies of
children with functional constipation (FC) or controls
following stimulation with secretagogues, as well as
expression of CFTR in those biopsies.
METHODS
Patients and biopsies
Between April 2006 and June 2009 children with FC according to
the Rome III criteria, who were resistant to laxative therapy and
were undergoing rectal suction biopsies to diagnose or to exclude
Hirschsprung’s disease participated into the study.17,18 Two
biopsies (up to 10–20 cm from the anal sphincter) of each patient
suspected for Hirschsprung’s disease were consecutively taken
upon endoscopy using a biopsy forceps with diameter 3.7 mm
(Olympus, Zoetermeer, The Netherlands). Two biopsies of chil-
dren without constipation, undergoing colonoscopy, to screen for
familial adenomatous polyposis, to remove juvenile polyps or to
screen for inflammatory bowel disease (IBD), were control biop-
sies. Biopsies of children with proven IBD or congenital defecation
disorders (Hirschsprung’s disease) were excluded from analysis.
Ussing chambers protocol
The colonic tissue obtained was transferred to ice-cold isotonic
medium composed of 136.9 mM NaCl, 2.7 mM KCL, 0.9 mM
CaCL22H2O, 0.5 mM Na2HPO4Æ12H2O, and 1.5 mM KH2PO4, pH
7.4. Then, the tissue was mounted in modified Ussing chambers
(window area 0.025 cm2). The tissue was short-circuited using a
dual voltage clamp (WPI, Berlin, Germany) and transepithelial
current changes in response to secretagogues added to the bath
were recorded ex vivo using Powerlab (AD Instruments, Spech-
bach, Germany).
Two biopsy specimens per patient were used for Ussing
chambers experiments. The bath solution was a modified Meyler
buffer composed of 105 mM NaCl, 4.7 mM KCL, 1.3 mM CaCL2Æ2-
H2O, 1.0 mM MgCL2Æ6H2O, 20.0 mM NaHCO3, 0.4 mM NaH2-
PO4ÆH2O, 0.3 mM Na2HPO4Æ2H2O, 10.0 mM HEPES, pH 7.4. The
tissue was kept at 37 C using hot water jackets. Carbogen
(95%O2/5% CO2) was constantly perfused through the chambers
to oxygenate the tissue. After mounting the tissue, indomethacin
was added to the bath to reduce the endogenous production of
prostaglandins. Thereafter, biopsy specimens were allowed to
equilibrate for 20 min to achieve stable measurements, after
which experimental treatments were applied.
As depicted in Fig. 1, first, amiloride (10 lM) was added to the
mucosal side of the tissue to inhibit the contribution of epithelial
Na+ channels (ENaC) to the current. The amiloride-sensitive
current (DIsc) was defined as the difference between baseline Isc
before and after addition of amiloride. After 10 min, the calcium-
linked secretagogue histamine (50 lM) was added to the serosal
side (S). Then, after reaching stable currents (10 min), another
calcium-linked secretagogue, carbachol (200 lM) was added to S.
Finally, after a new steady state was reached (ca. 10 min), a
cocktail of cAMP-linked agonists, forskolin (10 lM), and IBMX
(0.1 mM) was added to S.
Mechanisms of action of the secretagogues
in human colon
Histamine and carbachol stimulate chloride secretion mainly
through activation of calcium-dependent K+ channels (presumably
of the KCa3.1/SK4 type) in the basolateral membrane.19,20 The
resulting membrane hyperpolarization increases the electrochem-
ical driving force for Cl) exit through partially open CFTR
channels in the apical membrane. Forskolin stimulates chloride
secretion through adenylylcyclase activation and cAMP forma-
tion. Cyclic AMP, through activation of cAMP-dependent protein
kinase, phosphorylates and activates apical CFTR Cl) channels
and basolateral K+ channels (presumably KV7.1/KCNQ1).19,20
IBMX is a phosphodiesterase (PDE) inhibitor which indirectly
augments cAMP levels. All secretagogues result in stimulation of
chloride secretion with subsequent increase in Isc. The DIsc was
measured as the difference between baseline Isc (before addition of
the secretagogues) and the peak level of the Isc after addition of the
secretagogues.
Immunocytochemistry and confocal microscopy
Cryo-sections (8 lm) of human rectal biopsies were stored at
)80 C and analyzed according to the previously described
protocol by Broere et al., where sections were fixated for 10 min
with 4% paraformaldehyde and for 20 min in methanol, followed
by washing in 0.5% protifar (low-fat babymilk) and 0.15% glycine
in PBS, (=PBS+).21 Then, sections were incubated for 90 min in
PBS+ containing anti-CFTR monoclonal antibody (528, 1 : 50)
kindly donated by Prof. J.R. Riordan, University of North Carolina
Figure 1 Time line study protocol.
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at Chapel Hill).14 Subsequently, sections were washed with PBS+,
incubated for 60 min with Cy3-labeled anti-mouse IgG (1 : 100,
Jackson Immunoresearch Laboratory, West Grove, PA, USA)and
mounted with Vectashield (Vector Laboratories Inc., Burlingame,
CA, USA). Immunofluorescence micrographs were captured using
a ZeissLSM510 confocal microscope equipped with a 25 milliwatt
argonlaser. Fluorescence emission after excitation (488 nm for
CFTR) was detected using 10·/0.3 or 40·/1.3 numerical aperture
oil immersion lenses, a dichroic beam splitter reflecting 488-nm
excitation light, and a 505–530 bandpass emission filter. The
images were scanned using a 75-lm pinhole.
For (semi)quantification of signal from colonic crypts, images
from longitudinal sections at Z-steps of 0.5 lm were analyzed by
determining total background-subtracted fluorescent signal using
KS400 ZEISS software. The same threshold was utilized for all images
from one slide. Three individual crypts of each biopsy were
analyzed in a blinded fashion.
Medical ethical committee
All parents and children aged >12 years gave written consent. This
study was approved by the medical ethical committee of the
Academic Medical Centre of Amsterdam.
Statistical analysis
A sample size of 37 samples from each group was required to
achieve 80% power at a significance level of 0.05 to detect a
difference in means of twice the current change between the two
groups. Such a difference was anticipated on the basis of earlier
data by Bijlsma et al.22 The latter study performed in adult FC
patients showed preliminary evidence for a dramatically reduced
response to the secretagogues histamine and carbachol (by >85%)
in the epithelium of constipated patients. Baseline characteristics
and difference in change of current between constipated and
control tissue, were described and analyzed using the Student’s
t-test (SPSS version 14.0 statistical software, Chicago, IL, USA).
A P-value = 0.05 (two-tailed) was considered statistically significant.
RESULTS
Baseline characteristics of participating patients
A total of 46 children with FC (25 male) with mean
constipation duration of 3.6 ± 3.1 years and 50 (23
male) controls participated (Table 1, Fig. 2). Eighteen
patients (biopsies) were excluded in the FC group, one
set of biopsies was provided from a patient with a
congenital disease (trisomy 12) and eight other exper-
iments were excluded due to technical problems with
the equipment (see also Fig. 2). A total of 13 controls
were excluded, six patients had IBD and in seven
patients the experiments could not be conducted due to
technical problems. Equipment problems occurred
several times (in 15 patients, in six overlapping
sessions of experiments). These problems were diverse,
including electrical problems arising in the hospital,
inadequate temperature of the water jackets or com-
puter system failure.
Basal properties of human rectal mucosa
Under basal conditions, after 20 min stabilization in
the Ussing chamber, basal Isc of the control tissue
biopsies was 9.2 ± 0.8 lA cm)2 compared with
9.6 ± 1.1 lA cm)2 in the FC patients; P = 0.75.
Effect of amiloride and correlation with
defecation frequency
Amiloride caused a change in current of )11.8 ±
1.0 lA cm)2 in FC biopsies compared with )14.7 ±
2.2 lA cm)2 in control biopsies (P = 0.25). In consti-
pated and control biopsies, no correlation was found
between amiloride-induced current changes and defe-
cation frequency per week, (r = )0.01; P = 0.95 and
r = 0.01, respectively; P = 0.92).
Effect of secretagogues and correlation with
defecation frequency
As depicted in Table 2, carbachol induced a higher
current change in controls but this difference did not
reach statistical significance. However, if the working
Table 1 Baseline characteristics of the controls and patients with
functional constipation
Controls
(n = 37)
Constipation
(n = 37) P-value
Mean ± SE age (years) 10.7 ± 0.6 6.3 ± 0.6 <0.001
Duration constipation
symptoms (years)
– 3.6 ± 0.5 –
Mean ± SE defecation
frequency/week
10.0 ± 7.2 0.7 ± 1.2 <0.001
Mean ± SE fecal
incontinence
frequency/week
0.3 ± 0.1 8.2 ± 1.5 <0.001
Number of patients
with hard stool
consistency
2 25 <0.001
Total eligible patients
n = 96
Controls
n = 50
Excluded
n = 13
IBD n = 6
Equipment problems 
n = 7
Analyzed
n = 37
Constipation
n = 46
Excluded
n = 9
Cong. Syndrome n = 1
Equipment problems 
n = 8
Analyzed
n = 37
Figure 2 Flow chart of the participating patients.
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hypothesis is narrowed down to the question whether
carabachol-induced difference in current in FC patients
is lower than that in controls, which is allowed based
on the previously described results in adults by
Bijlsma, one-tailed testing shows a statistically signif-
icant P-value of 0.05.22
Histamine caused a current change of 24.5 ±
2.3 lA cm)2 in FC compared with 33.0 ± 3.0 lA cm)2
in controls (P = 0.028). In controls, a correlation was
found between the currents, following stimulation
with histamine (r = 0.4; P = 0.001) and carbachol
(r = 0.5; P < 0.001), and defecation frequency. No
correlation was found between defecation frequency
and currents following IBMX-forskolin (r = )0.2;
P = 0.24) in controls. In constipated biopsies no such
correlations were found with any secretagogue.
Correlation of the current responses with age
No correlation was found between age and amiloride-
induced current changes (r = )0.07; P = 0.43). Likewise
for the secretagogues histamine (r = )0.02; P = 0.80),
carbachol (r = )0.07; P = 0.44), and IBMX-forskolin
(r = )0.01; P = 0.9), no correlation was found with age.
Immunocytochemistry
As shown in Figs 3 and 4, CFTR immunostaining was
confined almost exclusively to the apical membrane of
colonic crypt cells, in agreement with a previous
immunolabeling study reporting the absence of apical
staining by the same monoclonal anti-CFTR antibody
in rectal biopsies from CF patients.14 Quantification of
the immunofluorescence-staining intensity of the
CFTR channel protein did not reveal a significant
difference between control and FC biopsies indicating
that the expression and distribution of CFTR protein
was not affected significantly by the FC condition.
DISCUSSION
In this study, we showed that calcium-linked chloride
secretion in the rectum is disturbed in constipated
children when compared to controls. Likewise, a
positive correlation was found between calcium-linked
chloride secretion, as induced by histamine and carba-
chol, and defecation frequency in control biopsies but
not in biopsies from constipated patients (FC). How-
ever, neither the amount of CFTR chloride channel
protein nor its apical localization in the colonic crypts
was affected by the FC condition.
To our knowledge this is the first study evaluating
chloride secretion in tissue of constipated children.
Constipated children had overall disturbed calcium-
linked chloride secretion but statistical significance
compared to non-constipated children was only
reached following stimulation with histamine.
Because the measurements are performed ex vivo and
the secretagogues are added exogenously, the reduction
in transepithelial chloride secretion in response to
histamine in the FC group cannot be explained by
possible differences in local histamine levels. Hista-
mine was only included in our protocol for its potent
calcium-linked secretagogue effect.23 However, just
recently a correlation between mast cells and nerve
fibers in rectal mucosa was found in children with
Table 2 Mean (±SE) change in current (DIsc:
lA cm)2) after adding amiloride, histamine,
carbachol, and forskolin/IBMX to the
mucosal (M) or serosal (S) bath in the Ussing
chamber
Controls
(n = 37)
Constipation
(n = 37)
P-value
two-tailed
P-value
one-tailed
Amiloride (M, 10 lM) )14.7 ± 2.2 )11.8 ± 7.0 0.25 –
Histamine (S, 50 lM) 33.0 ± 3.0 24.5 ± 2.3 0.03 –
Carbachol (S, 200 lM) 33.6 ± 3.4 26.4 ± 2.7 0.10 0.05
Forskolin (S, 10 lM) +
IBMX (S, 200 lM)
15.1 ± 2.2 15.4 ± 2.4 0.94 –
Figure 3 CFTR immunostaining of biopsies from controls.
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chronic constipation.24 In the latter study, constipated
children showed an increase in mast cell area. Consid-
ering the potential histamine release by mast cells,
exogenous histamine might not have reached its
optimal effect due to desensitization of the histamine
1 receptor in constipated children from our study.25,26
Given the latter, further research to elucidate the
possible role of mast cells and their mediators in
constipated children is justified.
Considering the diminished chloride secretory
response to calcium-linked secretagogues but not to
cAMP-linked secretagogues (forskolin-IBMX) in
constipated children, and the positive correlation of
defecation frequency with calcium dependent secreta-
gogues in controls, the disturbance in chloride secre-
tion in the FC group is most plausibly due to a defect in
intracellular calcium signaling. Whether this defect
occurs at the level of the histamine receptor, compo-
nents of the receptor-linked signal transduction
pathway (e.g., phospholipase C, inositol 1,4,5-trisphos-
phate-triggered calcium release), or basolateral Ca2+-
sensitive K+ channels (presumably SK4) that enhance
the electrical driving force for apical chloride secretion
through the CFTR Cl) channel, remains to be explored.
The transient character of the current response to
calcium-linked secretagogues, closely following the
transient increase in intracellular Ca2+, might suggest
that in constipated children an enhanced storage or
buffering capacity of intracellular Ca2+ rather than a
reduced mobilization could be responsible for the
difference in current changes. This is, however,
unlikely as we measured the maximal change in
current after secretagogues addition which occurred
within one minute, i.e., before the reuptake of calcium
into cellular reservoirs begins. Therefore, the CFTR
channel activator lubiprostone, which does not to elicit
a rise in cellular Ca2+ levels, would still be an obvious
candidate to treat children with constipation.7 The
latter is even more important as we found a positive
correlation of chloride secretion with defecation fre-
quency in controls.
In contrast to the findings with Ca2+-linked secret-
agogues, the chloride current response to cAMP-linked
agonists (IBMX-forskolin), was not different between
controls and constipated children. Moreover, the
expression level and apical distribution of the CFTR
protein in the colonic crypts was also not affected by
FC. Both findings strongly indicate that the compo-
nents of the cAMP signalling pathway, i.e., cAMP-
dependent protein kinase, apical CFTR chloride
channels, basolateral K+ channels (KCNQ1), and the
NaKCl2 co-transporter (NKCC1) were functioning
normally in the colon of the constipated children,
and stress the specificity of the defect in components of
the calcium signalling pathway that are not shared
with the cAMP pathway.
In adults, drugs stimulating chloride secretion are
already successfully applied in treating FC and IBS-
C.10,27 For children, no data are published concerning
treatment with those agents. Childhood FC treatment
encloses a combination of behavioral and medical
therapy. Polyethylene glycol (PEG) is the first line
drug used in these children and aims to soften
the stools, thereby contributing to a break-through of
the vicious circle of defecation avoidance caused by
pain during defecation.28 As only 60% of constipated
children accomplish successful treatment with PEG,
we recommend conducting randomized controlled
trials to assess the effect of PEG vs chloride secretion
stimulators such as lubiprostone or linaclotide.29
In conclusion, disturbed chloride secretion is found
in constipated children following stimulation with
histamine. Furthermore, calcium-dependent chloride
secretion was positively correlated with defecation
frequency in control biopsies. Given these results, it is
recommendable to conduct trials to investigate the role
of drugs stimulation chloride secretion in constipated
children.
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